miracl
trial
merscov
infect
treat
combin
lopinavirritonavir
investig
efficaci
combin
therapi
lopinavirritonavir
recombin
provid
standard
support
care
compar
placebo
provid
standard
support
care
hospit
patient
laboratoryconfirm
mer
miracl
trial
design
recurs
twostag
group
sequenti
multicent
placebocontrol
doubleblind
random
control
trial
aim
articl
describ
statist
analysi
plan
miracl
trial
primari
outcom
mortal
primari
analysi
follow
intentiontotreat
principl
miracl
trial
first
random
control
trial
mer
treatment
middl
east
respiratori
syndrom
mer
viral
respiratori
diseas
caus
middl
east
respiratori
syndrom
coronaviru
merscov
mer
case
continu
occur
often
associ
respiratori
multiorgan
failur
antivir
treatment
proven
efficaci
present
miracl
trial
merscov
infect
treat
combin
lopinavirritonavir
first
random
control
trial
mer
treatment
studi
protocol
previous
publish
sever
challeng
trial
treatment
diseas
like
mer
enough
inform
effect
size
lopinavirritonavir
provid
standard
support
care
compar
placebo
provid
standard
support
care
conduct
adequ
plan
studi
sampl
size
mer
sporad
unpredict
rare
diseas
make
difficult
plan
separ
pilot
studi
collect
necessari
inform
need
plan
main
trial
overcom
challeng
design
miracl
trial
recurs
twostag
adapt
trial
rel
new
method
group
sequenti
trial
approach
base
condit
error
principl
allow
flexibl
continu
adjust
trial
paramet
use
data
observ
prior
stage
without
inflat
type
error
anoth
advantag
method
flexibl
set
time
number
need
interim
analys
flexibl
necessari
situat
recruit
rate
unpredict
sudden
flux
recruit
patient
could
happen
time
final
design
take
advantag
accumul
inform
throughout
trial
everi
singl
recruit
patient
oppos
tradit
twostudi
approach
pilot
follow
main
trial
articl
describ
miracl
trial
statist
analysi
plan
sap
advanc
trial
complet
identifi
procedur
follow
primari
secondari
analys
trial
sap
written
studi
steer
committe
member
led
princip
investig
remain
blind
group
alloc
studi
result
complet
patient
recruit
patient
followup
complet
lock
databas
final
studi
report
follow
guidelin
consolid
standard
report
trial
consort
report
random
control
trial
trial
conduct
accord
standard
requir
good
clinic
practic
sap
develop
accord
intern
council
harmonis
guidelin
statist
principl
clinic
trial
clinic
studi
report
guidelin
guidelin
content
statist
analysi
plan
clinic
trial
miracl
trial
recurs
twostag
group
sequenti
multicent
random
placebocontrol
doubleblind
trial
trial
includ
hospit
patient
year
old
older
laboratoryconfirm
mer
addit
evid
acut
organ
dysfunct
judg
relat
mer
inclus
exclus
criteria
detail
previous
publish
protocol
manuscript
patient
random
receiv
lopinavirritonavir
recombin
placebo
random
stratifi
accord
center
accord
whether
patient
requir
mechan
ventil
invas
noninvas
time
enrol
mechan
ventil
major
pragmat
surrog
sever
ill
studi
intervent
continu
day
hospit
discharg
patient
follow
daili
day
hospit
discharg
day
consort
flow
diagram
trial
progress
construct
fig
number
random
patient
group
report
well
number
random
patient
receiv
intervent
also
report
number
screen
patient
defin
hospit
patient
mer
met
elig
criteria
enrol
reason
nonenrol
intentiontotreat
popul
consist
enrol
patient
whether
receiv
alloc
intervent
use
primari
analysi
perprotocol
analysi
conduct
patient
receiv
alloc
intervent
defin
dose
studi
intervent
baselin
characterist
present
two
studi
group
addit
file
tabl
includ
age
sex
bodi
mass
index
presenc
coinfect
nosocomi
versu
communityacquir
mer
infect
acut
physiolog
chronic
health
evalu
apach
ii
score
sequenti
organ
failur
assess
score
karnofski
perform
statu
scale
score
report
comorbid
intervent
receiv
random
patient
group
report
baselin
laboratori
valu
intern
normal
ratio
platelet
count
hemoglobin
white
blood
cell
count
lymphocyt
count
liver
enzym
glucos
serum
amylas
blood
urea
nitrogen
creatinin
creatin
kinas
lactat
respiratori
vital
paramet
addit
locat
patient
time
random
group
report
time
hospit
admiss
random
time
random
first
dose
receiv
studi
drug
report
receiv
studi
intervent
durat
group
addit
miss
incomplet
dose
protocol
violat
addit
file
tabl
tabl
compar
use
vasopressor
renal
replac
therapi
neuromuscular
blockad
mechan
ventil
extracorpor
membran
oxygen
ecmo
nitric
oxid
prone
ventil
tracheostomi
also
compar
use
intraven
immunoglobulin
antivir
therapi
antibiot
corticosteroid
statin
addit
file
tabl
primari
outcom
mortal
addit
file
tabl
primari
outcom
defin
allcaus
mortal
enrol
trial
within
day
either
inpati
outpati
secondari
outcom
subgroup
defin
present
tabl
addit
file
tabl
addit
compar
physiolog
paramet
among
patient
treat
treatment
group
control
group
analys
perform
use
sa
special
written
code
analysi
primari
supplement
oxygenfre
day
number
day
within
first
day
enrol
patient
receiv
supplement
oxygen
patient
die
within
day
assign
valu
renal
replac
therapyfre
day
number
day
within
first
day
enrol
patient
receiv
renal
replac
therapi
patient
die
within
day
assign
valu
vasopressorfre
day
number
day
within
first
day
enrol
patient
receiv
vasopressor
patient
die
within
day
assign
valu
invas
noninvas
mechan
ventilationfre
day
number
day
within
first
day
enrol
patient
receiv
mechan
ventil
patient
die
within
day
assign
valu
organ
supportfre
day
number
day
within
first
day
enrol
patient
receiv
invas
mechan
ventil
renal
replac
therapi
vasopressor
patient
die
within
day
assign
valu
extracorpor
circul
supportfre
day
number
day
within
first
day
patient
receiv
extracorpor
circul
support
patient
die
within
day
assign
valu
icufre
day
number
day
patient
care
icu
first
day
enrol
patient
die
within
day
assign
valu
postrandom
hospit
length
stay
number
day
random
discharg
hospit
compet
risk
effect
death
length
stay
length
stay
also
report
survivor
alon
number
percentag
report
seriou
advers
event
time
studi
period
sae
includ
acut
pancreat
sever
elev
alanin
aminotransferas
alt
fivefold
upper
normal
limit
anaphylaxi
bleed
diathesi
other
number
percentag
advers
event
grade
use
common
terminolog
criteria
advers
event
time
within
day
enrol
advers
drug
reaction
includ
allerg
reaction
gastrointestin
gener
nervou
system
other
see
also
tabl
function
outcom
karnofski
score
karnofski
perform
statu
scale
function
impair
scale
indic
normal
complaint
evid
diseas
indic
death
day
outcom
account
recurs
design
describ
chang
detail
interim
analysi
plan
report
miracl
protocol
trial
design
recurs
twostag
group
sequenti
random
trial
first
interim
analysi
conduct
subject
per
group
complet
day
followup
total
sampl
size
need
classic
design
classic
twogroup
design
requir
total
subject
subject
per
group
power
signific
level
use
onesid
z
test
differ
proport
detect
absolut
risk
reduct
day
mortal
among
subject
receiv
treatment
compar
control
group
data
safeti
monitor
board
dsmb
conven
review
unblind
data
efficaci
safeti
advis
continu
termin
trial
determin
stop
boundari
first
twostag
design
calcul
use
condit
power
method
base
sum
stagewis
p
valu
first
interim
analysi
dsmb
determin
whether
trial
termin
futil
use
follow
boundari
correspond
decis
tabl
summar
report
demograph
baselin
clinic
characterist
use
descript
statist
appropri
chisquar
test
fisher
exact
test
use
compar
categor
variabl
report
number
percentag
student
test
mannwhitney
u
test
use
appropri
compar
continu
variabl
report
mean
standard
deviat
median
interquartil
rang
advers
event
group
use
common
terminolog
criteria
advers
event
ctcae
version
nation
institut
health
nih
addit
file
tabl
advers
event
group
aggreg
group
report
entir
studi
period
addit
file
tabl
result
summar
term
frequenc
percentag
compar
across
studi
arm
use
fisher
exact
test
result
declar
statist
signific
p
valu
let
k
number
stage
current
clinic
trial
need
complet
trial
index
twostag
design
k
th
stage
let
r
r
proport
day
mortal
standard
care
treatment
group
respect
z
test
statist
differ
proport
calcul
follow
n
ki
sampl
size
per
group
th
twostag
design
k
th
stage
interim
analysi
ie
k
th
twostag
primari
outcom
evalu
trial
sampl
size
reestim
subsequ
stage
base
observ
effect
size
use
follow
formula
assum
condit
power
pc
decid
trial
continu
k
precalcul
reject
boundari
efficaci
second
stage
twostag
design
k
th
stage
p
k
raw
tabl
probabl
correspond
z
ki
statist
first
interim
analysi
data
suggest
anoth
stage
twostag
step
requir
recalcul
condit
error
new
boundari
calcul
k
let
k
k
reject
boundari
futil
efficaci
first
twostag
step
k
th
stage
condit
error
efficaci
stop
boundari
stop
trial
efficaci
second
stage
recalcul
base
condit
power
first
interim
analysi
maximum
probabl
threshold
trial
termin
earli
efficaci
maximum
probabl
threshold
trial
termin
futil
maximum
probabl
threshold
sum
stagewis
pvalu
studi
declar
met
endpoint
p
type
error
set
new
k
boundari
k
th
stage
pre
chosen
k
k
calcul
follow
end
trial
treatment
declar
efficaci
calcul
stagewis
order
p
valu
p
k
less
k
adjust
p
valu
obtain
use
backward
recurs
follow
k
total
number
twostag
stage
sum
stagewis
raw
p
valu
final
adjust
overal
onesid
confid
interv
calcul
k
stagewis
last
stage
kth
twostag
design
confid
interv
bound
last
stage
confid
bound
k
found
solv
follow
equat
numer
k
n
n
sampl
size
first
second
stage
last
k
th
twostag
design
p
p
stagewis
adjust
p
valu
order
stay
consist
method
use
calcul
boundari
trial
account
stratif
primari
outcom
analysi
gener
approach
accept
preserv
type
type
ii
error
long
weight
averag
effect
size
stay
close
hypothes
effect
size
furthermor
long
sampl
size
reestim
interim
analysi
base
weight
averag
effect
size
overal
power
trial
preserv
except
analysi
primari
outcom
analys
test
use
regular
statist
method
twosid
secondari
adjust
analysi
conduct
use
multipl
logist
regress
analysi
death
within
day
model
depend
variabl
set
baselin
variabl
strongli
believ
affect
outcom
mer
includ
independ
variabl
variabl
includ
minimum
follow
age
communityacquir
versu
hospitalacquir
infect
mechan
ventil
center
sequenti
organ
failur
assess
score
ninetyday
median
surviv
time
summar
report
use
kaplanmei
curv
compar
studi
group
use
logrank
test
addit
file
figur
analysi
secondari
outcom
compar
intentiontotreat
cohort
subgroup
analys
conduct
patient
number
permit
eg
fewer
five
patient
subgroup
interest
priori
defin
subgroup
addit
file
tabl
multivari
logist
regress
use
report
result
test
interact
subgroup
miss
data
review
character
term
pattern
eg
miss
complet
random
miss
random
etc
miss
complet
random
analys
base
listwis
delet
approach
observ
complet
valu
consid
analysi
variabl
valu
miss
random
multipl
imput
techniqu
util
imput
miss
valu
suggest
rubin
adjust
multipl
test
use
fals
discoveri
rate
fdr
describ
benjamini
hochberg
procedur
hypothesi
test
sort
ascend
order
base
calcul
p
valu
hypothesi
test
index
k
reject
k
calcul
follow
total
number
test
hypothes
q
addit
detail
sap
avail
addit
file
miracl
trial
investig
efficaci
combin
therapi
lopinavirritonavir
recombin
provid
standard
support
care
compar
placebo
provid
standard
support
care
hospit
patient
laboratoryconfirm
mer
first
patient
enrol
novemb
present
site
activ
screen
elig
patient
recruit
rate
miracl
trial
slow
mainli
relat
declin
number
mer
case
saudi
arabia
due
uncertainti
efficaci
level
treatment
recruit
rate
trial
design
recurs
twostag
group
sequenti
random
trial
sever
method
could
util
build
adapt
trial
howev
method
would
requir
one
specifi
priori
time
type
adjust
need
take
place
trial
diseas
mer
mani
factor
could
limit
abil
specifi
priori
element
thu
recurs
twostag
design
natur
choic
type
design
provid
enough
flexibl
introduc
differ
adjust
learn
observ
data
without
inflat
type
error
report
sap
miracl
trial
advanc
trial
complet
enhanc
evalu
clinic
data
support
confid
final
result
conclus
prior
specif
statist
method
outcom
analysi
facilit
unbias
analys
import
clinic
data
recruit
start
novemb
current
ongo
supplementari
inform
accompani
paper
http
addit
file
tabl
baselin
characterist
intentiontotreat
itt
popul
tabl
summari
intervent
cointervent
tabl
primari
outcom
mortal
tabl
secondari
outcom
tabl
subgroup
analys
tabl
classif
advers
event
miracl
trial
merscov
infect
treat
combin
lopinavirritonavir
use
nih
common
terminolog
criteria
advers
event
ctcae
version
tabl
summari
advers
event
sever
tabl
summari
protocol
violat
